Acurx Pharmaceuticals (ACXP) News Today → The #1 Investment of the Decade… (From Porter & Company) (Ad) Free ACXP Stock Alerts $2.16 -0.09 (-4.00%) (As of 05/16/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16 at 5:05 PM | insidermonkey.comAcurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q1 2024 Earnings Call TranscriptMay 16 at 7:57 AM | finance.yahoo.comAcurx Pharmaceuticals Inc (ACXP) Q1 2024 Earnings Call Transcript Highlights: Key Financial and ...May 16 at 2:56 AM | finance.yahoo.comQ1 2024 Acurx Pharmaceuticals Inc Earnings CallMay 16 at 1:08 AM | americanbankingnews.comAcurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Short Interest UpdateMay 15 at 9:56 PM | morningstar.comAcurx Pharmaceuticals Inc Ordinary SharesMay 15 at 10:02 AM | msn.comAcurx Pharmaceuticals GAAP EPS of -$0.28 misses by $0.04May 15 at 9:00 AM | prnewswire.comAcurx Announces Successful FDA End-of-Phase 2 Meeting and Phase 3 Readiness for Ibezapolstat in the Treatment of C. difficile InfectionMay 15 at 7:00 AM | prnewswire.comAcurx Pharmaceuticals, Inc. Reports First Quarter 2024 Results and Provides Business UpdateMay 8, 2024 | americanbankingnews.comAcurx Pharmaceuticals (ACXP) Scheduled to Post Quarterly Earnings on WednesdayMay 2, 2024 | finance.yahoo.comAcurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific ConferenceMay 2, 2024 | prnewswire.comAcurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific ConferenceApril 25, 2024 | prnewswire.comAcurx Pharmaceuticals Announces Presentation of Ibezapolostat Phase 2 Clinical Trial Results at upcoming ESCMID 2024 Scientific ConferenceApril 23, 2024 | prnewswire.comAcurx Pharmaceuticals, Inc. to Discuss First Quarter 2024 Financial Results on May 15, 2024 Conference Call and Provide Business UpdateApril 17, 2024 | nasdaq.comAcurx Pharmaceuticals Rings the Closing BellMarch 20, 2024 | seekingalpha.comAcurx Pharmaceuticals, Inc. (ACXP) Q4 2023 Earnings Call TranscriptMarch 19, 2024 | markets.businessinsider.comAcurx Pharmaceuticals: Strong Buy on Ibezapolstat’s Promising Phase 3 Trials and Strategic PartnershipsMarch 19, 2024 | finance.yahoo.comAcurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q4 2023 Earnings Call TranscriptMarch 19, 2024 | finance.yahoo.comQ4 2023 Acurx Pharmaceuticals Inc Earnings CallMarch 18, 2024 | investorplace.comACXP Stock Earnings: Acurx Pharmaceuticals Misses EPS for Q4 2023March 18, 2024 | finance.yahoo.comWe Think Acurx Pharmaceuticals (NASDAQ:ACXP) Needs To Drive Business Growth CarefullyMarch 18, 2024 | prnewswire.comAcurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business UpdateMarch 4, 2024 | prnewswire.comAcurx Pharmaceuticals, Inc. to Discuss Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024 Conference Call and Provide Business UpdateFebruary 27, 2024 | finance.yahoo.comAcurx Announces FDA Has Granted an End of Phase 2 Meeting for Ibezapolstat for C. difficile Infection and the European Medicines Agency Granted SME Designation for Ibezapolstat EU DevelopmentFebruary 27, 2024 | prnewswire.comAcurx Announces FDA Has Granted an End of Phase 2 Meeting for Ibezapolstat for C. difficile Infection and the European Medicines Agency Granted SME Designation for Ibezapolstat EU DevelopmentFebruary 17, 2024 | finance.yahoo.comACXP Mar 2024 4.000 callFebruary 16, 2024 | finance.yahoo.comACXP Mar 2024 5.000 putFebruary 2, 2024 | finance.yahoo.comNew to The Street Announces its 553rd Episode TV Line Up, Featuring Five Corporate Guests, Airing on the FOX Business Network, Monday, February 5, 2024, 10:30 PM PTFebruary 1, 2024 | finance.yahoo.comNew to The Street TV Announces Episode #552 with its Five Business Guest Interviews, Airs on Bloomberg TV as Sponsored Programming, Tonight, February 1, 2024, at 9:30 PM PTJanuary 26, 2024 | finance.yahoo.comNew to The Street Announces Episode 551, Five Corporate Interviews, Airing on the FOX Business Network, Monday, January 29, 2024, at 10:30 PM PTJanuary 23, 2024 | finance.yahoo.comAcurx Pharmaceuticals to Present at the Microcap Conference, January 31, 2024 - February 1, 2024January 17, 2024 | msn.comAcurx stock plunges 26% amid Phase 2 data release for C. diff drugJanuary 17, 2024 | msn.comELAB, KIND and RLX among pre-market losersJanuary 17, 2024 | markets.businessinsider.comAcurx Announces Positive Microbiology And Microbiome Data For Ibezapolstat From Phase 2b TrialJanuary 5, 2024 | finance.yahoo.comNew to The Street Announces its Four Corporate Interviews, Episode 543, Airing on the Fox Business Network, Monday, January 8, 2024, at 10:30 PM PTJanuary 3, 2024 | finance.yahoo.comAcurx to present at the 42nd Annual J.P. Morgan Healthcare ConferenceDecember 28, 2023 | benzinga.comAcurx Pharmaceuticals Stock (NASDAQ:ACXP), Guidance and ForecastDecember 15, 2023 | markets.businessinsider.comImpressive Phase 2b Results and Positive Outlook Justify Buy Rating for Acurx PharmaceuticalsDecember 13, 2023 | markets.businessinsider.comBuy Rating for Acurx Pharmaceuticals Stemming from Ibezapolstat’s Positive Phase 2b ResultsDecember 11, 2023 | msn.comWhy Acurx Pharmaceuticals (ACXP) Shares Are Falling TodayDecember 7, 2023 | finance.yahoo.comNew to The Street TV Announces Its Episode 536 Lineup, Five Corporate Guest Interviews, Broadcasted as Sponsored Program on Bloomberg TV, Tonight, Thursday, December 7, 2023, at 9:30 PM PTNovember 24, 2023 | finance.yahoo.comNew to The Street Announces its Five Business Guest Interviews, Episode 533, Airs on the FOX Business Network on Monday, November 27, 2023, at 10:30 PM PTNovember 17, 2023 | finance.yahoo.comNew to The Street Announces Episode 530 with Six Corporate Interviews, Airing on the Fox Business Network, Monday, November 20, 2023, at 10:30 PM PTNovember 15, 2023 | finance.yahoo.comAcurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q3 2023 Earnings Call TranscriptNovember 14, 2023 | benzinga.comAcurx Pharmaceuticals: Q3 Earnings InsightsNovember 14, 2023 | finance.yahoo.comAcurx Pharmaceuticals, Inc. Reports Third Quarter 2023 Results and Provides Business UpdateNovember 9, 2023 | finance.yahoo.com12 Best Day Trading Stocks To BuyNovember 3, 2023 | markets.businessinsider.comBuy Rating on Acurx Pharmaceuticals: Promising Clinical Results and Financial Stability Highlighted by Analyst Ed ArceNovember 2, 2023 | msn.comAcurx Pharma falls after mid-stage data for lead assetNovember 2, 2023 | msn.comAcurx Pharmaceuticals (ACXP) Price Target Increased by 8.82% to 12.58November 2, 2023 | finance.yahoo.comAcurx Announces Positive Top-Line Ibezapolstat Phase 2 Efficacy Results with 96% Clinical Cure Rate in Patients with C. difficile Infection Get Acurx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ACXP and its competitors with MarketBeat's FREE daily newsletter. Email Address Biden replacement revealed? (Ad)A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13. See his shocking evidence in this new report ACXP Media Mentions By Week ACXP Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACXP News Sentiment▼0.070.55▲Average Medical News Sentiment ACXP News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACXP Articles This Week▼121▲ACXP Articles Average Week Get Acurx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ACXP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Daré Bioscience News Viracta Therapeutics News Theratechnologies News NRx Pharmaceuticals News Enlivex Therapeutics News Spruce Biosciences News ImmunoPrecise Antibodies News Aprea Therapeutics News Fortress Biotech News Acasti Pharma News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ACXP) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersThe 1,000X Crypto PlaybookTrue Market InsidersGold Set to EXPLODE!Gold Safe ExchangeCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaMost important medical advance in 100 yearsThe Oxford ClubBill Clinton Backing Biden Replacement???The Freeport SocietyCharles Payne Demystifies OptionsUnstoppable Prosperity Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acurx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
